Pharmacokinetics and comparative bioavailability of two fenofibrate capsule formulations in healthy volunteers

Abstract

The objective of this study was to evaluate the pharmacokinetics of fenofibric acid, the main metabolite of fenofibrate (CAS 49562-28-9), and to assess the average bioequivalence of two immediate release formulations of 200 mg fenofibrate capsules in 24 healthy volunteers. The relative bioavailability of the test (generic) product Lipivim® with respect to the reference product was determined in a single dose, randomized, crossover study. Only the concentrations of fenofibric acid could be used for bioequivalence determination, because the concentrations of the parent drug were too low to be accurately measured in the biological matrix. The mean values for the C_max were 3.08 (± 1.69) μg/ml for the test and 3.05 (± 1.79) μg/ml for the reference product. The mean values for the AUC_0–∞ were 94.5 (±41.5) μg/ml h for the test and 88.2 (±41.4) μg/ml . h for thereference, respectively. The 90 % confidence intervals for test/reference mean ratios of the plasma pharmacokinetic variables C_max, AUC_0–t and AUC_0–∞ lie within the conventional bioequivalence range of 80 −125% (Schuirman test). The difference between T_max of the test and reference products was statistically non-significant (Friedman test). The test product is therefore bioequivalent to the reference product with respect to the rate and extent of fenofibric acid pharmacokinetics.

Key words

CAS 49562-28-9 - Fenofibrate, bioequivalence - Fenofibric acid, bioavailability, pharmacokinetics - Lipid-lowering agent

• References

• 1 Nearing GM, Ormrod D. Micronised fenofibrate: An updated review of its clinical efficacy m the management of dyslipidaemia. Drugs. 2002; 62: 1909-44
• 2 Adkins JC, Faulds D. Micronised fenofibrate: A review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia. Drugs. 1997; 54: 615-33
• 3 Guay DR. Update on fenofibrate. Cardiovasc Drug Rev. 2002; 20: 281-302
• 4 Najib J. Fenofibrate in the treatment of dyslipidemia: A review of the data as they relate to the new suprabioavailable tablet formulation. Clin Ther. 2002; 24: 2022-50
• 5 Hanafya A, Spahn-Langguthb H, Vergnaultc G, Grenierc P, TubicGrozdanisd M, Lenhardtd T et al Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug. Adv Drug Deliv Rev. 2007; 59: 419-26
• 6 Chena Y, Lua Y, Chenb J, Lai J, Sunb J, Huc F et al Enhanced bioavailability of the poorly water-soluble drug fenofibrate by using liposomes containing a bile salt. Int J Pharm. 2009; 376: 153-60
• 7 Midha KK, Rawson MJ, Hubbard JW. The role of metabolites in bioequivalence. PharmRes. 2004; 21: 1331-4
• 8 The European Agency for the Ealuation of Medicinal Products, Committee for proprietary medicinal products. Note for guidance on the investigation of bioavailability and bioequivalence. CPMP/EWP/QWP/1401/98. London, 26 July 2001
• 9 U. S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry. Bioavailability and Bioequivalence studies for orally administered drug products –general considerations. July 2002
• 10 Schuirmann DJ. A comparison of the two one-side test procedure and the power approach for assessment of the equivalence of average bioavailability. J Pharmacokinet Biopharm. 1987; 15: 657-80